论文部分内容阅读
自巴斯德研制出狂犬病粗制神经组织疫苗以来,各种人用狂犬病疫苗相继问世,其效力和安全性各不相同.如使用得当,新的细胞培养疫苗的保护率几达100%,且安全性很高.尽管如此,每年全世界仍有4万余人死于狂犬病.有些暴露前及暴露后的疫苗对照实验及临床研究表明,纯化的鸡胚细胞疫苗(PCEC)Rabipur的安全性和效力与人二倍体细胞疫苗(HDCV)相同,而后者是目前人用狂犬病疫苗的金标准.此外,用PCEC疫苗加强免疫不会诱生免疫介导的超敏反应,而使用HDCV时约6%的人会发生这样的超敏反应.
Since Pasteur developed a rabies-derived crude nerve tissue vaccine, a variety of human rabies vaccines have come into force one after another, with varying potencies and safety. With proper use, the new cell-culture vaccines have a protective rate of up to 100% However, there are still more than 40,000 deaths from rabies each year in the world, and some pre-exposure and post-exposure vaccine controlled trials and clinical studies have shown that the safety and efficacy of purified chicken embryo cell vaccine (PCEC) Rabipur and Is the same as human diploid cell vaccine (HDCV), which is the gold standard for the current human rabies vaccine and that boosting with PCEC does not induce an immune-mediated hypersensitivity, whereas HDCV is about 6 % Of people will have such a hypersensitivity reaction.